GU Cancers 2019 | Nrf2 inhibitors to overcome chemoresistance

Simon Crabb

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, talks about targeting Nrf2 signaling pathways to overcome resistance to chemotherapeutic agents in bladder cancer. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics
Related videos
1:36
Urothelial carcinoma: apatorsen plus docetaxel does not provide significant value
Petros Grivas
2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas
3:48
Urothelial carcinoma: maintenance therapies
Petros Grivas
4:20
IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
Thomas Powles
3:19
PD1 & PDL1 inhibitors for mUC, where are we?
Petros Grivas
Bladder Cancer, Genitourinary Cancer
Cisplatin
GU Cancers 2019
Interview
15th February 2019
More from Simon Crabb
ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC
Beyond cancer treatment: nurse specialists in the clinic
Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals